XVIVO is likely to enter 2025 with a modest quarter during a period of macro-economic worries.
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInve...
Redeye sees an interesting opportunity in Transtema, which is trading close to its four-year low des...
We believe organic growth could be negative y/y for Q1 2025.
Redeye comments on the acquisition announced this morning, where Dynavox Group acquires its long-tim...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by Next...
Relais announced today that it will acquire a majority stake in Matro Group, a well-established dist...
Umida Group AB (”Umida”, ”Koncernen” eller ”Bolaget”) meddelade den 7 april år 2025 att Bolaget har ...
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
Mangold återupptar bevakning av investmentbolaget Archelon Natural Resources "Archelon".
On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for rei...
Incorporating Doro lifts '26e-'27e EBITA by 25-53% We forecast a '25e-'28e EBITA CAGR of 32%.
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible...
Q1 report due 29 April We forecast net sales of SEK 589m, EBITA of SEK 92m We lower '25e-'27e EBITA ...
Redeye is pleased to note that Smart Eye announced two new design wins worth SEK200m today with an u...
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be...
Redeye initiates coverage of Tradedoubler, a leading digital network within affiliate and influencer...
Redeye provides a brief comment on Ependion’s acquisition of German company Welotec.
Redeye comments on the intriguing news that a newly published article in Nature highlights the poten...
